Genetic advances in sarcomeric cardiomyopathies: State of the art

Cardiovascular Research

Volumn 105, Issue 4, 2015, Pages 397-408

  Ho, Carolyn Y ^a   Charron, Philippe ^b,c   Richard, Pascale ^b   Girolami, Francesca ^d   Van Spaendonck Zwarts, Karin Y ^e   Pinto, Yigal ^e  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^d CAREGGI UNIVERSITY HOSPITAL   (Italy)

^e ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Dilated cardiomyopathy; Genetics; Hypertrophic cardiomyopathy; Next Generation Sequencing; Sarcomere

Indexed keywords

DNA; GENETIC MARKER;

BIOINFORMATICS; CARDIOMYOPATHY; CLINICAL GENETICS; DIGITAL FILTERING; DNA MODIFICATION; DNA SEQUENCE; EPIGENETICS; FAMILY HISTORY; GENE FUNCTION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC COUNSELING; GENETIC SCREENING; GENETIC VARIABILITY; GENOTYPE; GENOTYPE PHENOTYPE CORRELATION; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; INHERITANCE; MEDICAL TECHNOLOGY; MOLECULAR PATHOLOGY; NEXT GENERATION SEQUENCING; NONHUMAN; PATHOGENICITY; PATIENT CARE; PENETRANCE; PHENOTYPIC VARIATION; PREDICTIVE VALUE; PREVALENCE; PRIORITY JOURNAL; REVIEW; SARCOMERE; SEQUENCE ANALYSIS; SIGNAL NOISE RATIO; WHOLE EXOME SEQUENCING; WHOLE GENOME SEQUENCING; ANIMAL; BIOLOGY; CARDIOMYOPATHIES; GENE THERAPY; GENETIC MARKER; GENETIC PREDISPOSITION; GENETICS; METABOLISM; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; PATHOPHYSIOLOGY; PHENOTYPE; PROCEDURES; RISK FACTOR;

ANIMALS; CARDIOMYOPATHIES; COMPUTATIONAL BIOLOGY; DNA MUTATIONAL ANALYSIS; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; GENETIC THERAPY; HUMANS; MUTATION; PHENOTYPE; PREDICTIVE VALUE OF TESTS; RISK FACTORS; SARCOMERES;

EID: 84926640249     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvv025     Document Type: Review

References (94)

1. Geisterfer-Lowrance AA, Kass S, Tanigawa G, Vosberg HP, McKenna W, Seidman CE, Seidman JG. A molecular basis for familial hypertrophic cardiomyopathy: a beta cardiac myosin heavy chain gene missense mutation. Cell 1990;62:999-1006.
2. Kamisago M, Sharma SD, DePalma SR, Solomon S, Sharma P, McDonough B, Smoot L, Mullen MP, Woolf PK, Wigle ED, Seidman JG, Seidman CE. Mutations in sarcomere protein genes as a cause of dilated cardiomyopathy. N Engl J Med 2000;343:1688-1696.
3. McNally E, Dellefave L. Sarcomere mutations in cardiogenesis and ventricular noncompaction. Trends Cardiovasc Med 2009;19:17-21.
4. Mogensen J, Kubo T, Duque M, Uribe W, Shaw A, Murphy R, Gimeno JR, Elliott P, McKenna WJ. Idiopathic restrictive cardiomyopathy is part of the clinical expression of cardiac troponin i mutations. J Clin Invest 2003;111:209-216.
5. Jarcho JA, McKenna W, Pare JA, Solomon SD, Holcombe RF, Dickie S, Levi T, Donis-Keller H, Seidman JG, Seidman CE. Mapping a gene for familial hypertrophic cardiomyopathy to chromosome 14q1. N Engl J Med 1989;321:1372-1378.
6. Maron BJ, Gardin JM, Flack JM, Gidding SS, Kurosaki TT, Bild DE. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the cardia study. Coronary artery risk development in (young) adults. Circulation 1995;92:785-789.
7. Bos JM, Poley RN, Ny M, Tester DJ, Xu X, Vatta M, Towbin JA, Gersh BJ, Ommen SR, Ackerman MJ. Genotype-phenotype relationships involving hypertrophic cardiomyopathy-associated mutations in titin, muscle lim protein, and telethonin. Mol Genet Metab 2006;88:78-85.
8. Coats CJ, Elliott PM. Genetic biomarkers in hypertrophic cardiomyopathy. Biomark Med 2013;7:505-516.
9. Richard P, Charron P, Carrier L, Ledeuil C, Cheav T, Pichereau C, Benaiche A, Isnard R, Dubourg O, Burban M, Gueffet JP, Millaire A, Desnos M, Schwartz K, Hainque B, Komajda M. Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy. Circulation 2003;107: 2227-2232.
10. Saltzman AJ, Mancini-DiNardo D, Li C, Chung WK, Ho CY, Hurst S, Wynn J, Care M, Hamilton RM, Seidman GW, Gorham J, McDonough B, Sparks E, Seidman JG, Seidman CE, Rehm HL. Short communication: the cardiac myosin binding protein c arg502trp mutation: a common cause of hypertrophic cardiomyopathy. Circ Res 2010; 106:1549-1552.
11. Frank-Hansen R, Page SP, Syrris P, McKenna WJ, Christiansen M, Andersen PS. Microexons of the cardiac myosin binding protein c gene: flanking introns contain a disproportionately large number of hypertrophic cardiomyopathy mutations. Eur J Hum Genet 2008;16:1062-1069.
12. Maron BJ, Maron MS, Semsarian C. Genetics of hypertrophic cardiomyopathy after 20 years: clinical perspectives. J Am Coll Cardiol 2012;60:705-715.
13. Maron BJ, Haas TS, Goodman JS. Hypertrophic cardiomyopathy: one gene .. But many phenotypes. Am J Cardiol 2014;113:1772-1773.
14. Alpert NR, Mohiddin SA, Tripodi D, Jacobson-Hatzell J, Vaughn-Whitley K, Brosseau C, Warshaw DM, Fananapazir L. Molecular and phenotypic effects of heterozygous, homozygous, and compound heterozygote myosin heavy-chain mutations. Am J Physiol Heart Circ Physiol 2005;288:H1097-H1102.
15. Charron P, Carrier L, Dubourg O, Tesson F, Desnos M, Richard P, Bonne G, Guicheney P, Hainque B, Bouhour JB, Mallet A, Feingold J, Schwartz K, Komajda M. Penetrance of familial hypertrophic cardiomyopathy. Genet Couns 1997;8:107-114.
16. Watkins H, McKenna WJ, Thierfelder L, Suk HJ, Anan R, O'Donoghue A, Spirito P, Matsumori A, Moravec CS, Seidman JG, Seidman CE. Mutations in the genes for cardiac troponin t and alpha-tropomyosin in hypertrophic cardiomyopathy. N Engl J Med 1995;332:1058-1064.
17. Watkins H, Rosenzweig A, Hwang DS, Levi T, McKenna W, Seidman CE, Seidman JG. Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy. N Engl J Med 1992;326:1108-1114.
18. Charron P, Dubourg O, Desnos M, Bennaceur M, Carrier L, Camproux AC, Isnard R, Hagege A, Langlard JM, Bonne G, Richard P, Hainque B, Bouhour JB, Schwartz K, Komajda M. Clinical features and prognostic implications of familial hypertrophic cardiomyopathy related to the cardiac myosin-binding protein c gene. Circulation 1998;97: 2230-2236.
19. Niimura H, Bachinski LL, Sangwatanaroj S, Watkins H, Chudley AE, McKenna W, Kristinsson A, Roberts R, Sole M, Maron BJ, Seidman JG, Seidman CE. Mutations in the gene for cardiac myosin-binding protein c and late-onset familial hypertrophic cardiomyopathy. N Engl J Med 1998;338:1248-1257.
20. Maron BJ, Niimura H, Casey SA, Soper MK, Wright GB, Seidman JG, Seidman CE. Development of left ventricular hypertrophy in adults in hypertrophic cardiomyopathy caused by cardiac myosin-binding protein c gene mutations. J Am Coll Cardiol 2001;38:315-321.
21. Michels M, Soliman OI, Phefferkorn J, Hoedemaekers YM, Kofflard MJ, Dooijes D, Majoor-Krakauer D, Ten Cate FJ. Disease penetrance and risk stratification for sudden cardiac death in asymptomatic hypertrophic cardiomyopathy mutation carriers. Eur Heart J 2009;30:2593-2598.
22. Christiaans I, Birnie E, van Langen IM, van Spaendonck-Zwarts KY, van Tintelen JP, van den Berg MP, Atsma DE, Helderman-van den Enden AT, Pinto YM, Hermans-van Ast JF, Bonsel GJ, Wilde AA. The yield of risk stratification for sudden cardiac death in hypertrophic cardiomyopathy myosin-binding protein c gene mutation carriers: focus on predictive screening. Eur Heart J 2010;31:842-848.
23. Page SP, Kounas S, Syrris P, Christiansen M, Frank-Hansen R, Andersen PS, Elliott PM, McKenna WJ. Cardiac myosin binding protein-c mutations in families with hypertrophic cardiomyopathy: disease expression in relation to age, gender, and long term outcome. Circ Cardiovasc Genet 2012;5:156-166.
24. Pasquale F, Syrris P, Kaski JP, Mogensen J, McKenna WJ, Elliott P. Long-term outcomes in hypertrophic cardiomyopathy caused by mutations in the cardiac troponin t gene. Circ Cardiovasc Genet 2012;5:10-17.
25. Girolami F, Ho CY, Semsarian C, Baldi M, Will ML, Baldini K, Torricelli F, Yeates L, Cecchi F, Ackerman MJ, Olivotto I. Clinical features and outcome of hypertrophic cardiomyopathy associated with triple sarcomere protein gene mutations. J Am Coll Cardiol 2010;55:1444-1453.
26. Ingles J, Doolan A, Chiu C, Seidman J, Seidman C, Semsarian C. Compound and double mutations in patients with hypertrophic cardiomyopathy: implications for genetic testing and counselling. J Med Genet 2005;42:e59.
27. Marziliano N, Merlini PA, Vignati G, Orsini F, Motta V, Bandiera L, Intrieri M, Veronese S. A case of compound mutations in the mybpc3 gene associated with biventricular hypertrophy and neonatal death. Neonatology 2012;102:254-258.
28. Biagini E, Olivotto I, Iascone M, Parodi MI, Girolami F, Frisso G, Autore C, Limongelli G, Cecconi M, Maron BJ, Maron MS, Rosmini S, Formisano F, Musumeci B, Cecchi F, Iacovoni A, Haas TS, Bacchi Reggiani ML, Ferrazzi P, Salvatore F, Spirito P, Rapezzi C. Significance of sarcomere gene mutations analysis in the end-stage phase of hypertrophic cardiomyopathy. Am J Cardiol 2014;114:769-776.
29. Fujita T, Fujino N, Anan R, Tei C, Kubo T, Doi Y, Kinugawa S, Tsutsui H, Kobayashi S, Yano M, Asakura M, Kitakaze M, Komuro I, Konno T, Hayashi K, Kawashiri MA, Ino H, Yamagishi M. Sarcomere gene mutations are associated with increased cardiovascular events in left ventricular hypertrophy: results from multicenter registration in Japan. JACC Heart Fail 2013;1:459-466.
30. Li Q, Gruner C, Chan RH, Care M, Siminovitch K, Williams L, Woo A, Rakowski H. Genotype-positive status in patients with hypertrophic cardiomyopathy is associated with higher rates of heart failure events. Circ Cardiovasc Genet 2014;7:416-422.
31. Olivotto I, Girolami F, Ackerman MJ, Nistri S, Bos JM, Zachara E, Ommen SR, Theis JL, Vaubel RA, Re F, Armentano C, Poggesi C, Torricelli F, Cecchi F. Myofilament protein gene mutation screening and outcome of patients with hypertrophic cardiomyopathy. Mayo Clin Proc 2008;83:630-638.
32. Colan SD, Lipshultz SE, Lowe AM, Sleeper LA, Messere J, Cox GF, Lurie PR, Orav EJ, Towbin JA. Epidemiology and cause-specific outcome of hypertrophic cardiomyopathy in children: findings from the pediatric cardiomyopathy registry. Circulation 2007;115: 773-781.
33. Rapezzi C, Arbustini E, Caforio AL, Charron P, Gimeno-Blanes J, Helio T, Linhart A, Mogensen J, Pinto Y, Ristic A, Seggewiss H, Sinagra G, Tavazzi L, Elliott PM. Diagnostic work-up in cardiomyopathies: bridging the gap between clinical phenotypes and final diagnosis. A position statement from the esc working group on myocardial and pericardial diseases. Eur Heart J 2013;34:1448-1458.
34. Charron P, Arad M, Arbustini E, Basso C, Bilinska Z, Elliott P, Helio T, Keren A, McKenna WJ, Monserrat L, Pankuweit S, Perrot A, Rapezzi C, Ristic A, Seggewiss H, van Langen I, Tavazzi L. Genetic counselling and testing in cardiomyopathies: a position statement of the European society of cardiology working group on myocardial and pericardial diseases. Eur Heart J 2010;31:2715-2726.
35. Ackerman MJ, Priori SG, Willems S, Berul C, Brugada R, Calkins H, Camm AJ, Ellinor PT, Gollob M, Hamilton R, Hershberger RE, Judge DP, Le Marec H, McKenna WJ, Schulze-Bahr E, Semsarian C, Towbin JA, Watkins H, Wilde A, Wolpert C, Zipes DP. Hrs/ehra expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies this document was developed as a partnership between the heart rhythm society (hrs) and the european heart rhythm association (ehra). Heart Rhythm 2011;8:1308-1339.
36. Authors/Task Force m, Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P, Hagege AA, Lafont A, Limongelli G, Mahrholdt H, McKenna WJ, Mogensen J, Nihoyannopoulos P, Nistri S, Pieper PG, Pieske B, Rapezzi C, Rutten FH, Tillmanns C, Watkins H, Authors/Task Force m. 2014 esc guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the european society of cardiology (esc). Eur Heart J 2014;35:2733-2779.
37. Ingles J, McGaughran J, Scuffham PA, Atherton J, Semsarian C. Acost-effectiveness model of genetic testing for the evaluation of families with hypertrophic cardiomyopathy. Heart 2012;98:625-630.
38. Wordsworth S, Leal J, Blair E, Legood R, Thomson K, Seller A, Taylor J, Watkins H.DNA testing for hypertrophic cardiomyopathy: a cost-effectiveness model. Eur Heart J 2010; 31:926-935.
39. Christiaans I, van Langen IM, Birnie E, Bonsel GJ, Wilde AA, Smets EM. Quality of life and psychological distress in hypertrophic cardiomyopathy mutation carriers: a crosssectional cohort study. Am J Med Genet A 2009;149A:602-612.
40. Richard P, Denjoy I, Fressart V, Wilson MG, Carre F, Charron P. Advising a cardiac disease gene positive yet phenotype negative or borderline abnormal athlete: is sporting disqualification really necessary? Br J Sports Med 2012;46 (Suppl. 1):i59-i68.
41. Charron P, Heron D, Gargiulo M, Feingold J, Oury JF, Richard P, Komajda M. Prenatalmolecular diagnosis in hypertrophic cardiomyopathy: report of the first case. Prenat Diagn 2004;24:701-703.
42. Kuliev A, Pomerantseva E, Polling D, Verlinsky O, Rechitsky S. PGD for inherited cardiac diseases. Reprod Biomed Online 2012;24:443-453.
43. Mardis ER. Next-generation DNA sequencing methods. Annu Rev Genomics Hum Genet 2008;9:387-402.
44. Voelkerding KV, Dames SA, Durtschi JD. Next-generation sequencing: from basic research to diagnostics. Clin Chem 2009;55:641-658.
45. MacArthur DG, Manolio TA, Dimmock DP, Rehm HL, Shendure J, Abecasis GR, Adams DR, Altman RB, Antonarakis SE, Ashley EA, Barrett JC, Biesecker LG, Conrad DF, Cooper GM, Cox NJ, Daly MJ, Gerstein MB, Goldstein DB, Hirschhorn JN, Leal SM, Pennacchio LA, Stamatoyannopoulos JA, Sunyaev SR, Valle D, Voight BF, Winckler W, Gunter C. Guidelines for investigating causality of sequence variants in human disease. Nature 2014;508:469-476.
46. Sikkema-Raddatz B, Johansson LF, de Boer EN, Almomani R, Boven LG, van den Berg MP, van Spaendonck-Zwarts KY, van Tintelen JP, Sijmons RH, Jongbloed JD, Sinke RJ. Targeted next-generation sequencing can replace sanger sequencing in clinical diagnostics. Hum Mutat 2013;34:1035-1042.
47. Mamanova L, Coffey AJ, Scott CE, Kozarewa I, Turner EH, Kumar A, Howard E, Shendure J, Turner DJ. Target-enrichment strategies for next-generation sequencing. Nat Methods 2010;7:111-118.
48. Glenn TC. Field guide to next-generation DNA sequencers. Mol Ecol Resour 2011;11: 759-769.
49. Frommolt P, Abdallah AT, Altmuller J, Motameny S, Thiele H, Becker C, Stemshorn K, Fischer M, Freilinger T, Nurnberg P. Assessing the enrichment performance in targeted resequencing experiments. Hum Mutat 2012;33:635-641.
50. Lopes LR, Zekavati A, Syrris P, Hubank M, Giambartolomei C, Dalageorgou C, Jenkins S, McKenna W, Plagnol V, Elliott PM. Genetic complexity in hypertrophic cardiomyopathy revealed by high-throughput sequencing. J Med Genet 2013;50:228-239.
51. Norton N, Li D, Hershberger RE. Next-generation sequencing to identify genetic causes of cardiomyopathies. Curr Opin Cardiol 2012;27:214-220.
52. Rehm HL, Bale SJ, Bayrak-Toydemir P, Berg JS, Brown KK, Deignan JL, Friez MJ, Funke BH, Hegde MR, Lyon E. Acmg clinical laboratory standards for next-generation sequencing. Genet Med 2013;15:733-747.
53. Meder B, Haas J, Keller A, Heid C, Just S, Borries A, Boisguerin V, Scharfenberger-Schmeer M, Stahler P, Beier M, Weichenhan D, Strom TM, Pfeufer A, Korn B, Katus HA, Rottbauer W. Targeted next-generation sequencing for the molecular genetic diagnostics of cardiomyopathies. Circ Cardiovasc Genet 2011;4:110-122.
54. Mook OR, Haagmans MA, Soucy JF, van de Meerakker JB, Baas F, Jakobs ME, Hofman N, Christiaans I, Lekanne Deprez RH, Mannens MM. Targeted sequence capture and gs-flx titanium sequencing of 23 hypertrophic and dilated cardiomyopathy genes: implementation into diagnostics. J Med Genet 2013;50:614-626.
55. Schaefer E, Helms P, Marcellin L, Desprez P, Billaud P, Chanavat V, Rousson R, Millat G. Next-generation sequencing (ngs) as a fast molecular diagnosis tool for left ventricular noncompaction in an infant with compound mutations in the mybpc3 gene. Eur J Med Genet 2014;57:129-132.
56. Millat G, Chanavat V, Rousson R. Evaluation of a new ngs method based on a custom ampliseq library and ion torrent pgm sequencing for the fast detection of genetic variations in cardiomyopathies. Clin Chim Acta 2014;433:266-271.
57. Hershberger RE, Lindenfeld J, Mestroni L, Seidman CE, Taylor MR, Towbin JA. Genetic evaluation of cardiomyopathy-a heart failure society of America practice guideline. J Card Fail 2009;15:83-97.
58. Herman DS, Lam L, Taylor MR, Wang L, Teekakirikul P, Christodoulou D, Conner L, DePalma SR, McDonough B, Sparks E, Teodorescu DL, Cirino AL, Banner NR, Pennell DJ, Graw S, Merlo M, Di Lenarda A, Sinagra G, Bos JM, Ackerman MJ, Mitchell RN, Murry CE, Lakdawala NK, Ho CY, Barton PJ, Cook SA, Mestroni L, Seidman JG, Seidman CE. Truncations of titin causing dilated cardiomyopathy. N Engl J Med 2012;366:619-628.
59. Gupta P, Bilinska ZT, Sylvius N, Boudreau E, Veinot JP, Labib S, Bolongo PM, Hamza A, Jackson T, Ploski R, Walski M, Grzybowski J, Walczak E, Religa G, Fidzianska A, Tesson F. Genetic and ultrastructural studies in dilated cardiomyopathy patients: a large deletion in the lamin a/c gene is associated with cardiomyocyte nuclear envelope disruption. Basic Res Cardiol 2010;105:365-377.
60. Kloos W, Katus HA, Meder B. Genetic cardiomyopathies. Lessons learned from humans, mice, and zebrafish. Herz 2012;37:612-617.
61. Teekakirikul P, Kelly MA, Rehm HL, Lakdawala NK, Funke BH. Inherited cardiomyopathies: molecular genetics and clinical genetic testing in the postgenomic era. J Mol Diagn 2013;15:158-170.
62. Norton N, Li D, Rieder MJ, Siegfried JD, Rampersaud E, Zuchner S, Mangos S, Gonzalez-Quintana J, Wang L, McGee S, Reiser J, Martin E, Nickerson DA, Hershberger RE. Genome-wide studies of copy number variation and exome sequencing identify rare variants in bag3 as a cause of dilated cardiomyopathy. Am J Hum Genet 2011;88:273-282.
63. Wheeler M, Pavlovic A, DeGoma E, Salisbury H, Brown C, Ashley EA. A new era in clinical genetic testing for hypertrophic cardiomyopathy. J Cardiovasc Transl Res 2009;2: 381-391.
64. Ackerman MJ, Marcou CA, Tester DJ. Personalized medicine: genetic diagnosis for inherited cardiomyopathies/channelopathies. Rev Esp Cardiol (Engl Ed) 2013;66:298-307.
65. Caleshu C, Day S, Rehm HL, Baxter S. Use and interpretation of genetic tests in cardiovascular genetics. Heart 2010;96:1669-1675.
66. van El CG, Cornel MC, Borry P, Hastings RJ, Fellmann F, Hodgson SV, Howard HC, Cambon-Thomsen A, Knoppers BM, Meijers-Heijboer H, Scheffer H, Tranebjaerg L, Dondorp W, de Wert GM. Whole-genome sequencing in health care. Recommendations of the european society of human genetics. Eur J Hum Genet 2013;21 (Suppl. 1): S1-S5.
67. Norton N, Robertson PD, Rieder MJ, Zuchner S, Rampersaud E, Martin E, Li D, Nickerson DA, Hershberger RE. Evaluating pathogenicity of rare variants from dilated cardiomyopathy in the exome era. Circ Cardiovasc Genet 2012;5:167-174.
68. Richards CS, Bale S, Bellissimo DB, Das S, Grody WW, Hegde MR, Lyon E, Ward BE. Acmg recommendations for standards for interpretation and reporting of sequence variations: revisions 2007. Genet Med 2008;10:294-300.
69. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, Kondrashov AS, Sunyaev SR. A method and server for predicting damaging missense mutations. Nat Methods 2010;7:248-249.
70. Mestroni L, Taylor MR. Hearing the noise the challenges of human genome variation in genetic testing. J Am Coll Cardiol 2011;57:2328-2329.
71. Landstrom AP, Ackerman MJ. The achilles' heel of cardiovascular genetic testing: distinguishing pathogenic mutations from background genetic noise. Clin Pharmacol Ther 2011;90:496-499.
72. Ho CY. Genetics and clinical destiny: improving care in hypertrophic cardiomyopathy. Circulation 2010;122:2430-2440; discussion 2440.
73. Blankenburg R, Hackert K, Wurster S, Deenen R, Seidman JG, Seidman CE, Lohse MJ, Schmitt JP. Beta-myosin heavy chain variant val606met causes very mild hypertrophic cardiomyopathy in mice, but exacerbates hcm phenotypes in mice carrying other hcm mutations. Circ Res 2014;115:227-237.
74. Dorn GW 2nd, McNally EM. Two strikes and you're out: gene-gene mutation interactions in hcm. Circ Res 2014;115:208-210.
75. Kelly M, Semsarian C. Multiple mutations in genetic cardiovascular disease: a marker of disease severity? Circ Cardiovasc Genet 2009;2:182-190.
76. van Rijsingen IA, Hermans-van Ast JF, Arens YH, Schalla SM, de Die-Smulders CE, van den Wijngaard A, Pinto YM. Hypertrophic cardiomyopathy family with doubleheterozygous mutations; does disease severity suggest doubleheterozygosity? Neth Heart J 2009;17:458-463.
77. Lekanne Deprez RH, Muurling-Vlietman JJ, Hruda J, Baars MJ, Wijnaendts LC, Stolte-Dijkstra I, Alders M, van Hagen JM. Two cases of severe neonatal hypertrophic cardiomyopathy caused by compound heterozygous mutations in the mybpc3 gene. J Med Genet 2006;43:829-832.
78. Van Driest SL, Vasile VC, Ommen SR, Will ML, Tajik AJ, Gersh BJ, Ackerman MJ. Myosin binding protein c mutations and compound heterozygosity in hypertrophic cardiomyopathy. J Am Coll Cardiol 2004;44:1903-1910.
79. Jeschke B, Uhl K, Weist B, Schroder D, Meitinger T, Dohlemann C, Vosberg HP. A high risk phenotype of hypertrophic cardiomyopathy associated with a compound genotype of two mutated beta-myosin heavy chain genes. Hum Genet 1998;102:299-304.
80. Amin AS, Giudicessi JR, Tijsen AJ, Spanjaart AM, Reckman YJ, Klemens CA, Tanck MW, Kapplinger JD, Hofman N, Sinner MF, Muller M, Wijnen WJ, Tan HL, Bezzina CR, Creemers EE, Wilde AA, Ackerman MJ, Pinto YM. Variants in the 3' untranslated region of the kcnq1-encoded kv7.1 potassium channel modify disease severity in patients with type 1 long qt syndrome in an allele-specific manner. Eur Heart J 2012;33:714-723.
81. Wooten EC, Hebl VB, Wolf MJ, Greytak SR, Orr NM, Draper I, Calvino JE, Kapur NK, Maron MS, Kullo IJ, Ommen SR, Bos JM, Ackerman MJ, Huggins GS. Formin homology 2 domain containing 3 variants associated with hypertrophic cardiomyopathy. Circ Cardiovasc Genet 2013;6:10-18.
82. Perkins MJ, Van Driest SL, Ellsworth EG, Will ML, Gersh BJ, Ommen SR, Ackerman MJ. Gene-specific modifying effects of pro-lvh polymorphisms involving the reninangiotensin- aldosterone system among 389 unrelated patients with hypertrophic cardiomyopathy. Eur Heart J 2005;26:2457-2462.
83. Kolder IC, Michels M, Christiaans I, Ten Cate FJ, Majoor-Krakauer D, Danser AH, Lekanne Deprez RH, Tanck M, Wilde AA, Bezzina CR, Dooijes D. The role of renin-angiotensin-aldosterone system polymorphisms in phenotypic expression of mybpc3-related hypertrophic cardiomyopathy. Eur J Hum Genet 2012;20:1071-1077.
84. Olivotto I, Maron BJ, Tomberli B, Appelbaum E, Salton C, Haas TS, Gibson CM, Nistri S, Servettini E, Chan RH, Udelson JE, Lesser JR, Cecchi F, Manning WJ, Maron MS. Obesity and its association to phenotype and clinical course in hypertrophic cardiomyopathy. J Am Coll Cardiol 2013;62:449-457.
85. Schmitt JP, Semsarian C, Arad M, Gannon J, Ahmad F, Duffy C, Lee RT, Seidman CE, Seidman JG. Consequences of pressure overload on sarcomere protein mutationinduced hypertrophic cardiomyopathy. Circulation 2003;108:1133-1138.
86. Egger G, Liang G, Aparicio A, Jones PA. Epigenetics in human disease and prospects for epigenetic therapy. Nature 2004;429:457-463.
87. Bird A. Perceptions of epigenetics. Nature 2007;447:396-398.
88. Clarke SL, McKale R, Davis MS, Ramanjulu S. Biogenesis of mammalian mirna. In: Baron N. MicroRNA as Tools in Biopharmaceutical Production. Dordrecht: Springer; 2012.
89. Jinek M, Doudna JA. Athree-dimensional view of the molecular machinery ofRNAinterference. Nature 2009;457:405-412.
90. Forman JJ, Coller HA. The code within the code: microRNAs target coding regions. Cell Cycle 2010;9:1533-1541.
91. Meola N, Gennarino VA, Banfi S. Micrornas and genetic diseases. Pathogenetics 2009;2:7.
92. Oliveira-Carvalho V, da Silva MM, Guimaraes GV, Bacal F, Bocchi EA. Micrornas: new players in heart failure. Mol Biol Rep 2013;40:2663-2670.
93. van Rooij E, Olson EN. MicroRNAs: powerful new regulators of heart disease and provocative therapeutic targets. J Clin Invest 2007;117:2369-2376.
94. Jiang J, Wakimoto H, Seidman JG, Seidman CE. Allele-specificsilencing ofmutantmyh6transcripts in mice suppresses hypertrophic cardiomyopathy. Science 2013;342:111-114.